Plus Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Cerenome

15/08/2024 05:19

* Plus Therapeutics Inc  PSTV.OQ  reported a quarterly
adjusted
loss of 71 cents​​ per share for the quarter ended in June,
lower than the same quarter last year, when the company reported
EPS of -59 cents.  The mean expectation of three analysts for
the quarter was for a loss of 53 cents per share. Wall Street
expected results to range from -70 cents to -37 cents per share.
    * Revenue fell 31% to $1.28 million from a year ago;
analysts
expected $1.68 million. 
    * Plus Therapeutics Inc shares had risen by 1.4% this
quarter and
lost 14.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 29.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Plus Therapeutics
Inc is $26.50 
This summary was machine generated from LSEG data August 15 at
04:18 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.53          -0.71          Missed
 Mar. 31 2024      -1.09          -0.75          Beat
 Dec. 31 2023      -1.07          -0.84          Beat
 Sep. 30 2023      -1.12          -1.00          Beat